Scientist - Oral Product Development

Do you have expertise in, and passion for analytical science? Would you like to apply your expertise and be part of a company that follows the science and turns ideas into life changing medicines? Then AstraZeneca might be the one for you!

AstraZeneca is a major international healthcare business engaged in the research, development, manufacture and marketing of prescription pharmaceuticals and the supply of healthcare services. But we're more than one of the world's leading pharmaceutical companies. At AstraZeneca, we are proud to have a unique workplace culture that inspires innovation and collaboration. Here, employees are empowered to express diverse perspectives and are made to feel valued, energised and rewarded for their ideas and creativity.

In Pharmaceutical Technology and Development (PT&D), we are the bridge between forward-thinking science and innovative medicines that help millions of people. We work across the entire value chain, designing and delivering active ingredients, formulations and devices required to support new medicines - from supplies for use in early toxicology studies and clinical trials to developing the technology to ensure drugs can be scaled up for commercial manufacture.

We are currently looking for a Scientist in Oral Product Development (OPD). Our vision is to transform product design and development to enable us to deliver new medicines to patients. Oral products are a key growth area for AstraZeneca, covering a wide range of projects including small molecule immediate release, as well as modified release and complex formulations.

We're looking for a skilled and motivated scientist to join one of our analytical teams in Gothenburg, Sweden. This is an exciting opportunity where you will be key in developing our products, taking the next step into the future.

What you'll do

You will join a highly collaborative team developing analytical science and product development to the next level of efficiency, quality and innovation. You will work globally cross OPD and with our key partners in PT&D and commercial manufacturing sites.

You will get the opportunity to use your professional skills in a highly advanced research environment and contribute to the progression of drug product projects. You will be performing analysis with regards to drug product characterization and stability. You will also take part in analytical method development and validation, working closely together within the analytical project team. The role is primarily laboratory based.

Essential for the role

To be successful in this role you will need expertise in analytical chemistry and an experience from laboratory work. Excellent skills in written and verbal communication and the ability to engage and collaborate across boundaries with a positive problem-solving attitude and delivery focus.

* University degree (BSc, MSc) in relevant subject area, with industry experience
* Experience from laboratory work
* Experience from working with chromatography and other techniques e.g. HPLC/UPLC, and dissolution, both in a GxP and a non GxP environment
* Experience of the analytical area such as method development and method validation.
* Excellent communication skills and a proven track record of working collaboratively to develop innovative solutions

Please note applications shall include your CV and a cover letter which presents your areas of strength / development and why you should be considered for the role.

Why AstraZeneca

At AstraZeneca we're dedicated to being a Great Place to Work. Where you are empowered to push the boundaries of science and unleash your entrepreneurial spirit. There's no better place to make a difference to medicine, patients and society. An inclusive culture that champions diversity and collaboration, and always committed to lifelong learning, growth and development. We're on an exciting journey to pioneer the future of healthcare.

So, what's next? Are you ready to bring new ideas and fresh thinking to the table? Great! We welcome your application no later than 21st February, 2024.